Financials data is unavailable for this security.
View more
Year on year Regulus Therapeutics Inc 's net income fell 6.05% from a loss of 28.32m to a larger loss of 30.04m despite flat revenues.
| Gross margin | -- |
|---|---|
| Net profit margin | -- |
| Operating margin | -- |
| Return on assets | -63.31% |
|---|---|
| Return on equity | -72.36% |
| Return on investment | -71.29% |
More ▼
Cash flow in USDView more
In 2023, Regulus Therapeutics Inc did not generate a significant amount of cash. However, Cash Flow from Investing totalled 14.49m, indicating this company earned more from the sale of existing assets than it spent on the purchase of new assets. In addition the company used 26.77m for operations while cash generated from financing totalled 11.82m.
| Cash flow per share | -0.9231 |
|---|---|
| Price/Cash flow per share | -- |
| Book value per share | 1.33 |
|---|---|
| Tangible book value per share | 1.32 |
More ▼
Balance sheet in USDView more
| Current ratio | 14.14 |
|---|---|
| Quick ratio | -- |
| Total debt/total equity | 0.00 |
|---|---|
| Total debt/total capital | 0.00 |
More ▼
